- Home
- TCMD vs CLLS Comparison
TCMD vs CLLS Comparison
Compare TCMD & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCMD
- CLLS
- Stock Information
- Founded
- TCMD 1995
- CLLS 1999
- Country
- TCMD United States
- CLLS France
- Employees
- TCMD N/A
- CLLS N/A
- Industry
- TCMD Medical/Dental Instruments
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- TCMD Health Care
- CLLS Health Care
- Exchange
- TCMD Nasdaq
- CLLS Nasdaq
- Market Cap
- TCMD 300.1M
- CLLS 299.0M
- IPO Year
- TCMD 2016
- CLLS 2007
- Fundamental
- Price
- TCMD $13.70
- CLLS $3.08
- Analyst Decision
- TCMD Hold
- CLLS Buy
- Analyst Count
- TCMD 3
- CLLS 1
- Target Price
- TCMD $13.50
- CLLS $4.00
- AVG Volume (30 Days)
- TCMD 178.5K
- CLLS 71.4K
- Earning Date
- TCMD 11-03-2025
- CLLS 11-03-2025
- Dividend Yield
- TCMD N/A
- CLLS N/A
- EPS Growth
- TCMD N/A
- CLLS N/A
- EPS
- TCMD 0.63
- CLLS N/A
- Revenue
- TCMD $298,851,000.00
- CLLS $63,438,000.00
- Revenue This Year
- TCMD $8.85
- CLLS N/A
- Revenue Next Year
- TCMD $8.24
- CLLS $66.76
- P/E Ratio
- TCMD $22.01
- CLLS N/A
- Revenue Growth
- TCMD 6.15
- CLLS 223.09
- 52 Week Low
- TCMD $8.61
- CLLS $1.10
- 52 Week High
- TCMD $21.10
- CLLS $3.35
- Technical
- Relative Strength Index (RSI)
- TCMD 62.69
- CLLS 62.30
- Support Level
- TCMD $13.37
- CLLS $2.88
- Resistance Level
- TCMD $13.81
- CLLS $3.20
- Average True Range (ATR)
- TCMD 0.38
- CLLS 0.17
- MACD
- TCMD -0.06
- CLLS 0.02
- Stochastic Oscillator
- TCMD 74.53
- CLLS 68.24
About TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.